| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000094714 |
| P698 | PubMed publication ID | 16864979 |
| P2093 | author name string | Würtzen PA | |
| Knol EF | |||
| van Neerven RJ | |||
| Ejrnaes A | |||
| P2860 | cites work | A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation | Q47988492 |
| Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. | Q51644402 | ||
| Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. | Q51697508 | ||
| Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. | Q55034563 | ||
| Control of Exposure to Mite Allergen and Allergen-Impermeable Bed Covers for Adults with Asthma | Q57138398 | ||
| PROPHYLACTIC INOCULATION AGAINST HAY FEVER | Q57255078 | ||
| Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI) | Q24675347 | ||
| Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study | Q30307035 | ||
| Allergy and allergic diseases. First of two parts | Q33929836 | ||
| Allergy and allergic diseases. Second of two parts | Q33930765 | ||
| Omalizumab treatment downregulates dendritic cell FcepsilonRI expression | Q34281448 | ||
| Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper | Q34754637 | ||
| T cells and eosinophils in the pathogenesis of asthma | Q35273533 | ||
| Renaissance of the blocking antibody concept in type I allergy | Q35557996 | ||
| SEROLOGICAL EVIDENCE OF IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY FEVER). | Q36256769 | ||
| Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals | Q36362607 | ||
| Expression of functional high affinity immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic individuals | Q36362693 | ||
| Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 | ||
| Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. | Q40601643 | ||
| Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen | Q41022355 | ||
| Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells | Q41555930 | ||
| Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness | Q41843358 | ||
| IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy | Q44429951 | ||
| Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. | Q44467274 | ||
| Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. | Q44574133 | ||
| Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma | Q44917836 | ||
| The blocking activity of birch pollen-specific immunotherapy-induced IgG4 is not qualitatively superior to that of other IgG subclasses | Q47379187 | ||
| Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. | Q47602618 | ||
| Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. | Q47895314 | ||
| P433 | issue | 2 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 119-129 | |
| P577 | publication date | 2006-07-21 | |
| P1433 | published in | International Archives of Allergy and Immunology | Q2189251 |
| P1476 | title | IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy | |
| P478 | volume | 141 |
| Q46715031 | A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells |
| Q90181979 | Allergen Immunotherapy-Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite-Allergic Asthma Patients |
| Q33781950 | Allergen specific immunotherapy has no influence on standard chemistry and hematology laboratory parameters in clinical studies |
| Q37166041 | Allergen-specific IgG antibodies purified from mite-allergic patients sera block the IgE recognition of Dermatophagoides pteronyssinus antigens: an in vitro study |
| Q42153928 | Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy |
| Q38013789 | Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. |
| Q36749750 | B cells establish, but do not maintain, long-lived murine anti-peanut IgE(a). |
| Q47437171 | Blocking antibodies induced by allergen-specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model. |
| Q37660379 | CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. |
| Q36125684 | Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. |
| Q50358296 | Conformational IgE Epitope Mapping of Der p 2 and the Evaluations of Two Candidate Hypoallergens for Immunotherapy. |
| Q34361871 | Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy |
| Q37671347 | Cow's milk allergy: from allergens to new forms of diagnosis, therapy and prevention |
| Q42641649 | Determination of allergen specificity by heavy chains in grass pollen allergen-specific IgE antibodies |
| Q34508199 | Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1-specific monoclonal IgE. |
| Q47954707 | Distinct Expression and Function of FcεRII in Human B Cells and Monocytes |
| Q35113146 | Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposure |
| Q37900649 | Factors influencing the allergenicity and adjuvanticity of allergens. |
| Q27011839 | Food allergies: the basics |
| Q36565528 | Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. |
| Q38773340 | Grass pollen immunotherapy: where are we now. |
| Q35577578 | Identification of novel peptide biomarkers to predict safety and efficacy of cow's milk oral immunotherapy by peptide microarray |
| Q36403601 | IgE, but not IgG4, antibodies to Ara h 2 distinguish peanut allergy from asymptomatic peanut sensitization |
| Q33770788 | IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. |
| Q54417521 | IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. |
| Q50918275 | IgG4: not only for allergists. |
| Q46042780 | Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells |
| Q38861295 | Markers of tolerance development to food allergens. |
| Q37958561 | Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives |
| Q37847222 | Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens |
| Q83472421 | Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells |
| Q27682039 | Relationships between IgE/IgG4 Epitopes, Structure and Function in Anisakis simplex Ani s 5, a Member of the SXP/RAL-2 Protein Family |
| Q38930093 | Relationships between T cell and IgE/IgG4 epitopes of the Anisakis simplex major allergen Ani s 1. |
| Q35420502 | Specific immunotherapy in atopic dermatitis. |
| Q39335284 | Structure of the omalizumab Fab. |
| Q50941015 | The majority of allergen-specific IgE in the blood of allergic patients does not originate from blood-derived B cells or plasma cells. |
| Q36983712 | The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses |
| Q92435887 | The use of biologics for immune modulation in allergic disease |
| Q36099147 | The usefulness of casein-specific IgE and IgG4 antibodies in cow's milk allergic children |
| Q42362492 | Tracing antigen signatures in the human IgE repertoire |
| Q37732900 | Update on Biomarkers to Monitor Clinical Efficacy Response During and Post Treatment in Allergen Immunotherapy |
| Q37965722 | mRNA vaccination as a safe approach for specific protection from type I allergy. |
Search more.